CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
✉ Email this page to a colleague
All Clinical Trials for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00383929 ↗ | Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg | Completed | AstraZeneca | Phase 3 | 2006-09-01 | In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5 mg to that of candesartan 32 mg alone in patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and candesartan/HCT 32/12.5 mg with that of candesartan 32 mg, respectively. |
| NCT00434967 ↗ | Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo | Completed | AstraZeneca | Phase 3 | 2007-01-01 | The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults. |
| NCT00621153 ↗ | Candesartan Effect in Second Stage Arterial Hypertension | Completed | AstraZeneca | Phase 4 | 2008-02-01 | To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen |
| NCT01012479 ↗ | Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension | Completed | Takeda | Phase 4 | 2009-10-01 | The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension. |
| NCT02016183 ↗ | Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months) | Completed | Takeda | 2009-04-01 | The purpose of this study is to evaluate the safety and efficacy of long-term use of candesartan cilexetil / hydrochlorothiazide combination tablets (ECARD) Combination Tablets LD&HD in hypertensive patients in the routine clinical setting | |
| NCT02094924 ↗ | A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 | Completed | GlaxoSmithKline | Phase 1 | 2014-04-17 | This study is required to confirm the suitability of a candidate FDC of 16mg candesartan cilexetil/12.5mg HCTZ (GSK587323) formulation for further development and provide data to allow the design of a future pivotal bioequivalence study. This study aims to determine the relative bioavailability of a FDC tablet formulation of 16mg candesartan cilexetil/12.5mg HCTZ relative to the reference product of same fixed dose combination (16mg candesartan cilexetil/12.5mg HCTZ) in healthy adult humans. This will be an open-label, randomised, single dose, two-way crossover study. Each subject will participate in two treatment periods and will be randomized to one of two sequences and administered one of the two treatments, A or B, as per the randomization schedule. The two treatment periods will be separated by a washout period of 7 to 14 days to ensure the candesartan and HCTZ have been effectively eliminated from the subject between dosing occasions. The study will enroll 16 healthy subjects to ensure that 14 subjects complete the study as planned. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Condition Name
Clinical Trial Locations for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Clinical Trial Progress for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase
Clinical Trial Sponsors for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Sponsor Name
